Belluscura announces filing of a patent application covering novel portable extracorporeal oxygenation and carbon dioxide removal systems for the treatment of acute respiratory distress syndrome (ARDS)

BelluscuraNews

LONDON, UK AND PLANO, TX  Belluscura PLC, in conjunction with its exclusive research partner Separation Design Group, announced today the recent filing of a patent application covering novel integrated portable extracorporeal oxygenation and carbon dioxide removal systems.

The latest patent application covers systems for treating people suffering from acute respiratory distress syndrome (ARDS).  Typical causes of ARDS include sepsis, inhalation of harmful chemicals and smoke, injury, pneumonia and influenza.  It is estimated that in the US and Europe alone, over 300,000 people annually suffer from ARDS with an estimated mortality rate of nearly 40%.

Commenting on the patenting activities, Bob Rauker, CEO of Belluscura, said: “We are very excited about our next generation oxygen technology.  With the anticipated launch of our X-PLO2R™ portable oxygen concentrator later this year into the respiratory treatment field where over 250 million people suffer from chronic obstructive pulmonary disease (COPD), the third leading cause of death, it is critical that we continue to innovate into the ever-expanding oxygen therapy market”.

Background to Belluscura

Belluscura (www.belluscura.com) was established in the UK in December 2015 with the objective of improving healthcare through innovation.  We are currently developing a proprietary oxygen concentrator system with a planned commercial release in 2019 that will be used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions such as COPD, asthma, occupational lung diseases and pulmonary hypertension.

This Press Release contains forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company’s intentions, beliefs or current expectations concerning, among other things, the Company’s results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future.  These forward-looking statements speak only as of the date of this Press Release and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Press Release.

www.belluscura.com

Contact:               Investor Relations

Name:                  CEO

e-mail:                  investor@belluscura.com

phone:                 1-214-396-8313